NL-OMON38158已完成2 期
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinoma - JAEM (219-390)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients will be at least 18 years old with histologically or cytologically confirmed Stage IV (AJCC edition 7) nonsquamous NSCLC. Patients may have either measurable or nonmeasurable disease based on the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v. 1.1), and must have ECOG status of 0 or 1 as well as adequate hematologic, coagulation, and organ function. Patients must have fasting serum glucose < 125 mg/dL (6.9 mmol/L), and hemoglobin A1C <= 6%.
排除标准
- •Patients must not have an uncontrolled intercurrent illness, leptomeningeal disease, or active infection requiring parenteral therapy.
研究者
相似试验
进行中（未招募）
1 期
A Study in Non-Small Cell Lung Canceradvanced nonsquamous non-small cell lung carcinomaMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024014-60-DEEli Lilly and Company Limited, Indianapolis156
进行中（未招募）
1 期
A Study in Non-Small Cell Lung Canceradvanced nonsquamous non-small cell lung carcinomaMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024014-60-BEEli Lilly and Company Limited, Indianapolis156
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesEUCTR2020-004175-41-ITeoImmuneTech, Inc.127
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesAdvanced or metastatic gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC) progressed on or intolerant to 2 or more prior lines of systemic therapyMedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082464Term: Advanced gastric carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.1Level: LLTClassification code 10084873Term: Gastrooesophageal junction cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10079913Term: Adenocarcinoma of the gastroesophageal junction stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030145Term: Oesophageal adenocarcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004175-41-ESeoImmuneTech, Inc.127
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of the combination of durvalumab with azacitidine to treat a cancer of the bone marrow, causing cancer cell proliferation and improper normal blood cell production.Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2015-003596-30-PLCelgene International II Sàrl182